North Star Asset Management Inc. Raises Stock Position in Stryker Corporation $SYK

North Star Asset Management Inc. boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 2.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 101,686 shares of the medical technology company’s stock after purchasing an additional 2,194 shares during the quarter. Stryker comprises approximately 1.4% of North Star Asset Management Inc.’s holdings, making the stock its 16th biggest position. North Star Asset Management Inc.’s holdings in Stryker were worth $35,740,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SYK. Brighton Jones LLC increased its holdings in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares in the last quarter. Schnieders Capital Management LLC. purchased a new position in Stryker in the second quarter valued at $205,000. Marshall Wace LLP increased its holdings in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after buying an additional 77,831 shares in the last quarter. Nebula Research & Development LLC purchased a new position in Stryker in the second quarter valued at $219,000. Finally, HUB Investment Partners LLC purchased a new position in Stryker in the second quarter valued at $253,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. The trade was a 28.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Up 0.9%

Shares of NYSE SYK opened at $316.39 on Friday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87. The stock has a market cap of $121.29 billion, a PE ratio of 36.62, a P/E/G ratio of 1.99 and a beta of 0.80. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average of $325.22 and a 200 day moving average of $349.82.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SYK shares. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Canaccord Genuity Group cut their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Piper Sandler reaffirmed an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Finally, UBS Group decreased their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a report on Tuesday, March 17th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.